<DOC>
	<DOCNO>NCT02941107</DOCNO>
	<brief_summary>Australian Indigenous child , particularly living remote community , suffer disproportionately high burden rotavirus gastroenteritis disease . Despite introduction rotavirus vaccine Northern Territory ( NT ) Immunisation Schedule 2006 , rate hospitalization rotavirus NT Aboriginal child &lt; 5 year continue high , rate ratio rotavirus hospitalisation Indigenous versus non-Indigenous child actually increase . The reason sub-optimal vaccine response completely understood , reduced vaccine immune response low vaccine coverage likely important factor . The purpose study determine Aboriginal child receive additional dose RV1 age 6 12 month , increase anti-rotavirus serum IgA seroconversion decrease medical presentation gastroenteritis first three year life , compare receive placebo .</brief_summary>
	<brief_title>Optimising Rotavirus Vaccine Aboriginal Children</brief_title>
	<detailed_description />
	<mesh_term>Gastroenteritis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged â‰¥ 6 month &lt; 12 month Identified Aboriginal and/or Torres Strait Islander and/or South Sea Islander per attend legally responsible caregiver/parent . Have receive either one two prior dos RV1 vaccination confirm check immunisation register . Legally responsible caregiver/parent willing infant participate study aware requirement protocol . Legally responsible caregiver/parent willing allow party involve treatment child ( include general practitioner , medical centre staff medical professional child may patient duration trial ) notify participation trial participation trial record within Northern Territory Immunisation Register . The legally responsible caregiver/parent willing allow study team obtain vaccination history Northern Territory Immunisation Register and/or Australian Childhood Immunisation Register ( ACIR ) and/or local provider . The legally responsible caregiver/parent willing allow study team obtain medical history hospitalisation laboratory database , disease notification register , participant 's electronic medical record and/or participant 's primary care provider period enrolment age 36 month Informed consent infant's/child 's participation study give legally responsible caregiver/parent Has contraindication RV1 vaccination include : Severe combine immunodeficiency , history intussusception , history hypersensitivity vaccine component , uncorrected gastrointestinal tract malformation , receipt two week immunosuppressant immune modifying drug , ( e.g . prednisolone &gt; 0.5mg/kg/day ) within 28 day enrolment , confirm suspect severe immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection Receipt rotavirus vaccination RV1 Receipt previous 3 month blood product include immunoglobulin Has receive investigational vaccines/drugs , vaccine use study , within 30 day prior receive vaccine dose ; plan use study period second visit 28 55 day Has receive prior dos &gt; two prior dos RV1 vaccination Medical condition treatment medication opinion clinic staff would make child unsuitable trial Previously enrol trial</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Aboriginal</keyword>
	<keyword>Rotavirus</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Diarrhoea</keyword>
</DOC>